MCM
DTIL icon

MAI Capital Management’s Precision BioSciences DTIL Stock Holding History

MAI Capital Management’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7
Closed -$39 – 2781
2026
Q1 		$39 Hold
7
– – ﹤0.01% 4899
2025
Q4 		$30 Hold
7
– – ﹤0.01% 4280
2025
Q3 		$39 Hold
7
– – ﹤0.01% 3767
2025
Q2 		$30 Hold
7
– – ﹤0.01% 3925
2025
Q1 		$34 Hold
7
– – ﹤0.01% 3398
2024
Q4 		$27 Buy
+7
New +$51 ﹤0.01% 3462

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

MAI Capital Management's DTIL Position: Q2 2026 in Review

MAI Capital Management sold out of Precision BioSciences (DTIL) in Q2 2026, closing a stake of 7 shares — an estimated $39 sold.

MAI Capital Management first reported a position in DTIL in Q4 2024 and held it in 6 quarters. The position peaked at $39 in Q1 2026. 95 funds tracked by Wall St. Rank hold DTIL as of Q2 2026.

  • MAI Capital Management reported no remaining Precision BioSciences position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 7 Precision BioSciences shares in Q2 2026, an estimated $39.
  • MAI Capital Management first reported a position in Precision BioSciences in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Precision BioSciences position peaked at $39 in Q1 2026.
  • 95 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.